Results 61 to 70 of about 21,298 (206)

Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline [PDF]

, 2016
PURPOSE: To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of ...
Barbara Fowble, Debra L. Barton, Erin Macrae, Gibson L, Hannah Klein Connolly, Harold J. Burstein, Hope S. Rugo, Hyman B. Muss, James L. Khatcheressian, James N. Ingle, Johnston SR, Larissa A. Korde, Lesley Fallowfield, Maura N. Dickler, Mohammad Jahanzeb, R. Bryan Rumble, Rita S. Mehta, Stephen R.D. Johnston, Suman VJ, Wilcken N   +19 more
core   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

The Effectiveness of Fulvestrant in postmenopausal advanced breast cancer; systematic review of clinical evidence

Journal of Pharmacoeconomics and Pharmaceutical Management, 2015
Background: In this study we aim to assess the clinical evidence on the effectiveness of Fulvestrant compared with other alternatives to explore whether it has any advantage in the treatment outcomes of postmenopausal advanced breast cancer or not ...
Amir Hashemi-Meshkini, Khosro Keshavarz, Mehdi Varmaghani, Abbas Kebriaeezadeh, Shekoufeh Nikfar   +4 more
doaj  

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2− advanced or metastatic breast cancer

Frontiers in Pharmacology
ObjectiveThe aim of this study was to compare the cost-effectiveness of various CDK4/6 inhibitors plus fulvestrant with fulvestrant monotherapy in the second-line treatment for patients with HR+/HER2− advanced or metastatic breast cancer from the Chinese
Kaixuan Wang, Shixian Liu, Shunping Li, Jie Gao   +3 more
doaj   +1 more source

Nonylphenol and octylphenol differently affect cell redox balance by modulating the nitric oxide signaling [PDF]

, 2018
Nonylphenol (NP) and octylphenol (OP) are pervasive environmental contaminants belonging to the broader class of compounds known as alkylphenols, with potential human toxic effects.
Arese, Marzia, Magnifico, MARIA CHIARA, Popov, Milica, Sarti, Paolo, Saso, Luciano, Xhani, Marla   +5 more
core   +3 more sources

Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 3, May 2026.
Abstract Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnostic (CDx) assay (FOLR1‐2.1, Ventana).
Annika Nasdala, Leonie D Kandt, Martin Radner, Nora Schaumann, Malte Gronewold, Pia Hillmann, Henriette Christgen, Jens Hachenberg, Elna Kuehnle, Christian Hartmann, Matthias Christgen   +10 more
wiley   +1 more source

Antitumor Activity of Sodium Selenite, Palbociclib, and Disulfiram Against Osteosarcoma and Rhabdomyosarcoma Cell Lines

Drug Development Research, Volume 87, Issue 3, May 2026.
ABSTRACT Osteosarcoma and rhabdomyosarcoma are the most common pediatric sarcomas, yet prognosis remains poor due to high relapse rates. This study investigates the repurposing of palbociclib (PB) and disulfiram (DS), alongside sodium selenite (SS), as potential therapeutic strategies.
María Ángeles Chico, Kevin Doello, Raul Ortiz, Mercedes Peña, Consolación Melguizo, Cristina Mesas, Jose Prados   +6 more
wiley   +1 more source

Alpelisib therapy: from theory to practice

Медицинский совет, 2022
Before the development and implementation of the first PI3K inhibitor (alpelisib), the presence of a mutation in the PIK3CA gene had only prognostic value: it determined the unfavorable course of luminal HER2-negative metastatic breast cancer (testing ...
E. V. Lubennikova, T. A. Titova, I. P. Ganshina   +2 more
doaj   +1 more source

Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome [PDF]

, 2012
BACKGROUND: McCune-Albright Syndrome (MAS) is usually characterized by the triad of precocious puberty (PP), fibrous dysplasia, and café au lait spots. Previous treatments investigated for PP have included aromatase inhibitors and the estrogen receptor ...
Charles Sultan, Emily K Sims, Erica A Eugster, Franco Guzman, Françoise Paris, null null, Sally Garnett   +6 more
core   +1 more source

Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with ...
Oluwadamilola Onasanya, Seyed Hamidreza Mahmoudpour, Benjamin Bates, Irene M. Shui, Geoffrey Liu, Eng Hooi Tan, Yi‐Hsin Yang, Maribel Salas, Joseph Fadare, Dimitri Bennett, Paula Lana de M. Drummond, Judy Ju‐Young Shin, Sonia Guleria, Jocelyn R. Wang, Manila Hada, Helene Denis, Soko Setoguchi, Ilse Truter, Luciane C. Lopes, Ruth Wangia Dixon   +19 more
wiley   +1 more source